A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Conditions:   Pancreatic Cancer;   BRAF Mutant Colorectal Cancer;   Other Tumor Types With Documented Genetic Alterations Upstream in the Wnt Signaling Pathway;   Melanoma;   Triple Negative Breast Cancer;   Head and Neck Cancer
Interventions:   Drug: LGK974;   Biological: PDR001
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2017

http://ift.tt/2lutDcv